Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 13, 2005 W.D. Crotty	Is Connetics Saving Face? The FDA is making its mark on this specialty pharmaceutical stock, but there are opportunities to rebound.
The Motley Fool January 25, 2010 Brian Orelli	No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday.
The Motley Fool June 30, 2010 Brian Orelli	Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth?
The Motley Fool May 18, 2010 Brian Orelli	What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool January 23, 2004 Alyce Lomax	Amgen's Engine Is the drug company geared up for success?
The Motley Fool February 26, 2011 Brian Orelli	FDA Applications and a Look Ahead It isn't pretty.
The Motley Fool February 18, 2004 Jeff Hwang	Elan's Early Submission Elan and Biogen Idec will submit a multiple sclerosis treatment ahead of schedule.
The Motley Fool July 21, 2010 Brian Orelli	Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive.
The Motley Fool February 10, 2010 Brian Orelli	Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool May 10, 2004 Roger Nusbaum	Uh-Oh for Cisco A blowout earnings report may not be enough to lift Cisco.
The Motley Fool June 11, 2009 Brian Orelli	The FTC Hates You, Too The agency weighs in (unhappily) on follow-on biologics.
The Motley Fool August 17, 2004 Charly Travers	Surviving Biotech's Downturns Advice on withstanding the volatility of the biotech sector.
The Motley Fool February 12, 2004 Seth Jayson	ValueClick Keeps Vaulting The online marketing provider launches to another 52-week high.
The Motley Fool March 3, 2009 Brian Orelli	Stop Worrying About Follow-On Biologics They're inevitable, but they won't hurt biotech as much as you might think.
The Motley Fool February 6, 2004 Rick Aristotle Munarriz	Look Away, LookSmart An online search specialist gets ready for a fall.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool December 20, 2007 Brian Orelli	2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something.
The Motley Fool May 5, 2006 Stephen D. Simpson	Biogen Idec Needs a Booster Tysabri had better come back strong, or growth could come up short for this biotech. Investors, take note.
The Motley Fool July 30, 2004 Rich Smith	Career Education's Class Rank Career Education is one of the cheaper companies in the education sphere.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool June 25, 2007 Brian Orelli	Leading the Pack of Follow-On Drug Makers Generic drug maker Dr. Reddy's Laboratories is taking a huge risk to get ahead of the pack, but it's well worth the rewards of being in front of its competitors. Investors, take note.
The Motley Fool February 8, 2005 Charly Travers	Good Prognosis for Biogen IDEC Blockbuster products help the biotech firm continue its stellar performance.
The Motley Fool February 10, 2004 David Nierengarten	The Psoriasis Wars The pharma heavies are battling for the chronic skin disease's market.
The Motley Fool May 26, 2004 Charly Travers	Elan and Biogen File for Approval There's a new multiple sclerosis drug on the horizon.
The Motley Fool January 30, 2004 Alyce Lomax	No Hollywood Star Competitive concerns loom over Hollywood Entertainment's long-term growth plans.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool January 6, 2004 Jeff Hwang	Hollywood Hammered Hollywood Entertainment warns again, but are its shares cheap at nine times earnings?
The Motley Fool February 9, 2004 Rex Moore	InterActive Closes Impressive Year The Internet commerce conglomerate is still growing strong.
The Motley Fool March 23, 2004 David Nierengarten	Genentech's Star Power How much higher can Genentech go?
The Motley Fool February 20, 2004 Bill Mann	Things Left Unsaid A company puts its best foot forward in a press release, but old releases can tell a different story.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool April 21, 2004 Rich Smith	Career Education's Big Lesson The online educator Career Education rakes in stellar earnings, exceeding analyst estimates again.
The Motley Fool April 29, 2004 Rick Aristotle Munarriz	InfoSpace Heater InfoSpace is just plain profitable.
The Motley Fool April 5, 2004 Jeff Hwang	Siebel Out of Surprises The company's raised guidance follows a familiar conservative approach.
The Motley Fool February 23, 2005 Brian Gorman	Amgen Gets Disciplined Direct-to-consumer advertising may be a non-starter for Amgen and other biotech companies.
The Motley Fool December 31, 2007 Brian Lawler	The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.
The Motley Fool April 8, 2004 Charly Travers	Indevus' Big Score (Maybe) A small biotech company lands a potentially rich deal.
InternetNews May 27, 2004 Paul Shread	Tech Data Surprises The biggest earnings blowouts seem to be coming from the most unlikely places lately.
The Motley Fool March 29, 2004 W.D. Crotty	OraSure Not That Sure Its oral-fluid HIV test is a breakthrough, but the stock isn't cheap.
The Motley Fool April 16, 2004 Rich Smith	DoubleClick's Pinched Penny Rounding earnings per share can lay traps for unwary investors. Online advertiser DoubleClick becomes a good lesson in why it is best to think of those little ticker symbols scrolling by as pieces of companies rather than little ticker symbols.
The Motley Fool April 21, 2004 Rick Munarriz	Hail to the Jeeves Online content providers continue to rock in 2004 -- just Ask Jeeves. Paid search is the place to be.
The Motley Fool March 4, 2004 Chris Mallon	Nasdaq Snoozing Nasdaq investors had a great year in 2003, as the index soared 50% from start to finish. From its post-bubble low of 1,114, the composite index has nearly doubled, topping out recently at 2,153.83
The Motley Fool January 25, 2005 Charly Travers	Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs.
InternetNews June 15, 2004 Paul Shread	Oracle Investors Get Picky Oracle beat estimates after the close on Tuesday, but investors proved to be tough to please.
The Motley Fool August 28, 2006 Brian Lawler	The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks.